Dr. Nath on the Interim Results of the SIERRA Trial in Relapsed/Refractory AML

Video

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

Rajneesh Nath, MD, hematologist/oncologist, Banner Health, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia (AML).

The ongoing SIERRA trial (NCT02665065) randomized patients 1:1 to receive a conditioning regimen comprised of targeted radiation with Iomab-B plus hematopoietic stem cell transplant or conventional care. Interim results from the study, which were presented during the 2021 Transplantation and Cellular Therapy Meetings, showed that 4.2% of patients became septic on the Iomab-B regimen vs 30% on standard therapy vs 23.3% who crossed over to the Iomab-B regimen from the standard regimen.

The hypothesis that powered the study suggested that utilizing a myeloablative, targeted conditioning therapy would mitigate toxicities, particularly within the gastrointestinal tract, explains Nash. In turn, patients would have less mucositis, febrile neutropenia, and sepsis. Although only 75% of the total estimated patient population were included, the findings are statistically significant and clinically meaningful, concludes Nash.

Related Videos
Alessandra Ferrajoli, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Dipti Patel-Donnelly, MD, Johns Hopkins
Rebecca L. Porter, MD, PhD
Deborah J. Wong, MD, PhD
Michael R. Migden, MD